Imprint control regions, or ICRs, are stretches of DNA carrying methylation marks that are laid down before gastrulation, very early in embryonic development, and then faithfully copied through every subsequent cell division. Because one parental allele is methylated while the other remains unmethylated, imprinted genes are expressed from a single copy, making them exquisitely sensitive gene dosage regulators. When these marks are disturbed, the consequences can be severe: imprinting abnormalities underlie Prader-Willi and Angelman syndromes, Silver-Russell and Kagami-Ogata syndromes, a range of cancers, neurological disorders, and chronic diseases linked to environmental contaminants. Because the marks are stable across tissues and across the life course, they also act as long-term molecular records of early-life exposures that questionnaires and conventional exposure assessments cannot recover.

The motivation for the new array stems from a 2022 study in which Dereje Jima and colleagues used whole-genome bisulfite sequencing, or WGBS, to map 1,488 candidate differentially methylated ICRs across the human genome. Before that work, only 24 human ICRs had been well characterized. WGBS remains the reference method because it can, in principle, read every CpG site in the genome, including all 22,157 CpG positions that fall within the newly catalogued ICRs. But it is expensive, demands high sequencing coverage, requires substantial computational infrastructure, and is impractical for the large sample numbers that epidemiological studies of chronic disease require. Existing targeted alternatives are similarly limited: pyrosequencing handles only short single sequences, pooled amplicon sequencing works only for small preselected target sets, and hybridization capture approaches such as targeted methyl-seq demand specialized instrumentation and expertise.

Commercial arrays offered no better solution. The Infinium Methylation EPIC v1 BeadChip covers just 1.4 percent of the CpG sites in the candidate ICRs, representing only 156 of the 1,488 regions with an average of two probes each. The newer EPIC v2 array improves on that, reaching 6.8 percent of the sites and 548 ICRs, but still leaves most of the imprintome unmeasured. To close this gap, the research team, led by Natalia Carreras-Gallo and Ryan Smith of TruDiagnostic together with Cathrine Hoyo, David Skaar, Randy Jirtle and colleagues at North Carolina State University and other institutions, extracted the 22,157 ICR-mapped CpG sites from the hg38 reference genome and worked with Illumina to design probes against them, applying the company’s validated quality thresholds for sequence, GC content and annealing temperature.

The resulting Human Imprintome array carries 22,819 probes in total, including 704 control probes and 22,115 CG probes. Of the CG probes, 10,438 target unique CpG sites, and 9,757 of those align successfully within the candidate ICR catalogue, covering 1,088 of the 1,488 regions, or 73.1 percent, with an average of nine probes per region and a maximum of 171. The design also retains 10,364 background-normalization probes and 1,313 multimapping probes, which were kept because they represent many ICRs but flagged with zeroed coordinates to prevent misassignment. Coverage remains sparse for ICRs on chromosomes 1 through 5 and chromosome 21, where repetitive sequence produces the most multimapping probes, and roughly 400 ICRs currently lack representation altogether, a limitation the team says it is already working to fix in a next version.

Validation proceeded along two fronts. First, the researchers processed matched samples on both the Human Imprintome array and the EPIC v2 array, using whole blood samples from an Alzheimer’s disease cohort recruited at the Duke Memory Clinic. Across 1,703 overlapping probe sites, Pearson correlation coefficients between the two platforms reached 0.788, 0.811 and 0.789 in the three samples tested, with a mean R-squared of 0.796. Notably, the beta-value distributions told a mechanistically satisfying story: while the full probe set of the Imprintome array showed peaks at methylation values of zero, one half and one, the subset of probes mapped to ICRs collapsed to a single dominant peak at one half, exactly the signature expected of parent-of-origin methylation in which one allele is fully methylated and the other fully unmethylated.

Second, the team compared the array against WGBS, the current gold standard, using sixteen autopsy brain specimens from the Duke/UNC Alzheimer’s Disease Research Center brain bank, comprising equal numbers of Alzheimer’s cases and controls among non-Hispanic Black and non-Hispanic White donors. Samples were pooled within each of four groups to boost sequencing coverage, which ranged from 10X to 15X with bisulfite conversion above 97 percent. After filtering CpG sites with fewer than ten sequencing reads, correlations between array and sequencing measurements ranged from 0.532 to 0.657, with a mean R-squared of 0.569. The authors attribute the lower agreement relative to the EPIC v2 comparison to the modest WGBS coverage and to fundamental differences between array-based and sequencing-based methylation measurement, rather than to any flaw in the array itself.

Reliability testing reinforced the platform’s credentials. Eight umbilical cord blood samples from the Newborn Epigenetics Study, a prospective birth cohort of 2,681 pregnant women recruited in Durham, North Carolina between 2005 and 2011, and seventeen whole blood samples from the Alzheimer’s cohort were each run twice on the Imprintome array. Intraclass correlation coefficients between replicate runs ranged from 0.799 to 0.945, with a mean of 0.868, indicating that the array delivers highly reproducible measurements, a prerequisite for biomarker development and for multi-center studies where batch effects and platform drift can otherwise swamp true biological signals.

The practical advantages of the new tool extend beyond coverage. Because it is built on the familiar Infinium BeadChip platform, it slots into existing laboratory workflows, from bisulfite conversion of 200 nanograms of DNA through hybridization on the iScan imaging system, and into established bioinformatic pipelines, including the sesame R package, which the authors used for preprocessing and which supports custom array manifests. Arrays are faster, cheaper and more automatable than next-generation sequencing for the targeted question of ICR methylation, and by concentrating probes on regions of interest, a custom array avoids paying for genome-wide content irrelevant to the research question. The team has also released comprehensive annotations of every probe and its ICR assignments, and plans to make data and resources available through the humanicr.org website.

The broader promise is considerable. With environmental and lifestyle factors estimated to account for 70 to 90 percent of the burden of common chronic diseases, yet with disease often emerging decades after exposure, stable early-established epigenetic marks are among the few measurable archives of developmental history the human body keeps. A reliable, scalable readout of the imprintome could accelerate the discovery of ICRs associated with cancer, neurological disease, imprinting syndromes and environmentally driven illness, sharpen causal inference in exposure epidemiology, and guide therapeutic strategies aimed at growth regulation and developmental disorders. For a field that until recently could name only two dozen human imprint control regions, the arrival of a dedicated, validated array marks a decisive step toward making the full imprintome a routine object of study rather than a specialized pursuit.

Subject of Research: Development and validation of a custom Infinium DNA methylation array for profiling human imprint control regions

Article Title: Creation and validation of the first infinium DNA methylation array for the human imprintome

Article References: Carreras-Gallo, N., Dwaraka, V. B., Jima, D. D., Skaar, D. A., Mendez, T. L., Planchart, A., Zhou, W., Jirtle, R. L., Smith, R., & Hoyo, C. (2024). Creation and validation of the first infinium DNA methylation array for the human imprintome. Epigenetics Communications, 4(1), Article 5. https://doi.org/10.1186/s43682-024-00028-6

Image Credits: AI Generated

DOI: 10.1186/s43682-024-00028-6

Keywords: genomic imprinting, imprintome, imprint control regions, DNA methylation, Infinium array, methylation array, epigenetics, whole-genome bisulfite sequencing, EPIC v2, custom BeadChip, environmental epigenetics, Alzheimer's disease

The round tables were designed around the framework of Responsible Research and Innovation, or RRI, an approach that has gained traction over the past decade in both academia and science policy. Unlike traditional ethical, legal, and social implications research, which treats ethics as an external check on finished technologies, RRI asks scientists to embed social and ethical reflection into the earliest stages of research itself. This is no small ask. Studies cited in the report show that many natural scientists see themselves as responsible only for the quality of their research, viewing societal consequences as the domain of regulators and oversight bodies operating downstream in a linear model of innovation. The term responsibility, researchers have found, can even be perceived as accusatory by scientists who feel that RRI policies are imposed by outsiders unfamiliar with the realities of laboratory work.

To avoid these pitfalls, the organizers built the discussions around two concrete case studies tailored to the actual technical frontiers of epigenetics. Ten tables of roughly eight participants each, moderated and blended across seniority, gender, and research interests, spent forty minutes debating guided vignettes before their note-takers submitted minutes for thematic analysis. The first case examined whether epigenetic editing, a nascent family of technologies that rewrites gene expression without altering the DNA sequence, is ready to move from bench to bedside. The second probed whether environmental epigenetics, the study of how exposures shape chemical tags on the genome, is mature enough to inform regulatory risk assessment of chemical safety.

The clinical case centered on a striking proof-of-principle published in Nature in 2024. Using lipid nanoparticles to deliver a so-called hit-and-run epigenetic editor, researchers silenced the Pcsk9 gene in mice, stably reducing plasma cholesterol for eleven months without the editor persisting in the cells. The promise is obvious: a one-time therapy that could replace daily statin adherence, which is undermined by forgetfulness, side effects, and poor awareness. Round table participants largely agreed that a single-administration therapy would be preferable to recurrent medication, provided safety and efficacy standards were met. Yet the conversation quickly grew more complicated. One group argued that epigenetic editing should only become a standard treatment if it offers clear additional benefits over existing drugs. Others questioned the economics, noting that the global statin market was valued at over sixteen billion dollars in 2023 and suggesting that biotechnology companies may simply be eyeing a shift of pharmaceutical profits rather than genuine cost savings for patients.

Beneath the commercial questions lay deeper scientific uncertainties. Participants agreed that knowledge of the long-term and off-target effects of epigenetic editing is far too thin for clinical deployment. Delivery of synthetic editors into cells remains problematic, and little is known about how editing behaves differently across cell types. Stability of the induced modifications, a precondition for any durable therapy, has been demonstrated only in limited windows, and cells may well fight back to restore their original epigenetic state, potentially requiring regular epigenome and transcriptome monitoring. Reversibility is equally underexplored, yet participants considered it essential: clinicians would need the ability to revert cells to their original state should severe side effects emerge. Some groups raised the specter of cancer or autoimmune responses, and while a few speculated about impacts on future generations, the participants emphasized that no consensus exists on intergenerational epigenetic inheritance in humans.

The discussions also surfaced concerns about equity and biological complexity. Without diverse reference epigenomes, widespread therapeutic editing could accrue existing health inequalities, a risk participants proposed to mitigate through more diverse basic research, representative clinical trials, and parallel development of alternative treatments. Two groups cautioned against simplistic views of safety, warning that even an on-target edit could trigger a domino effect through regulatory networks, with downstream consequences for genes far removed from the intended target. Yet one participant pushed back with a pointed rhetorical question about a double standard: do we know the on-target systemic effects of aspirin, and if not, why should epigenetic technologies be held to a stricter evidentiary bar than established drugs? In an unprompted turn, several groups also discussed public outreach, worrying that patients might be frightened by the phrase gene editing and suggesting the technology may even need a new name.

The second case, on environmental epigenetics and chemical regulation, produced an even more sobering assessment. Participants from six tables found common ground that current epigenetic evidence is not ready to support the regulation or prohibition of substances. There are no known unique epigenetic signatures for specific exposures, and the same stress response can be triggered by different chemicals, making it nearly impossible to dissect the contribution of any single component of a person’s exposome. No standardized methods exist to establish what minimal epigenetic change can be meaningfully interpreted as functional disease risk, so results are hard to interpret and difficult to reproduce. Tissue access compounds the problem: researchers can mostly measure blood, swabs, urine, and feces, even though organs like the brain, highly relevant to stress research, remain inaccessible, and different tissues react differently to chemicals. Animal models offer only limited translational value because of differing lifespans and epigenetic drift.

Challenges inherent to epigenetic biology itself deepened the pessimism. Genetic background can confound exposure studies, as illustrated by a 2017 finding that children carrying a common PON1 gene variant showed adverse cardio-metabolic methylation profiles only when prenatally exposed to pesticides, implying that identical exposures produce different risk profiles depending on the individual. Route of intake, dose chronology, exposure windows from pregnancy to old age, and interacting contexts like the microbiome, diet, and socioeconomic status all modulate epigenetic effects, which are themselves small against multifactorial disease backgrounds. Participants questioned whether statistical epigenetic data would even add value beyond existing epidemiological correlations, and they flagged societal risks of their own science: stigmatization of prospective parents, echoing what pregnant smokers already face, and the potential misuse of epigenetic data by insurers, a scenario participants urged governments to regulate proactively. As a path forward, groups called for standardized methods, large prospective cohorts, bioinformatic integration of heterogeneous data, and honest debate about whether the community has a responsibility to push epigenetic testing into regulatory science, even as the tobacco saga shows policymakers can resist decades of harm evidence.

Perhaps the report’s most striking finding is the divergence of views on what all this means for translation. One camp sees the field’s immaturity as a solvable practical challenge, pointing to accumulating safety data on editing platforms and the slow advance of epigenetic endpoints in toxicology. A second, more cautious group doubts that data harmonization and standardization can ever fully succeed. A third views the complexity of the epigenome, shaped by environment, stochasticity, and gene-environment interplay, as a fundamental barrier that no methodology will overcome, rendering cause-and-effect disentanglement effectively impossible. Meanwhile, a few participants questioned whether demanding complete knowledge before translation is an unreasonable standard at all, noting that two epigenetic editing clinical trials have already received medical-ethical approval. The authors tentatively attribute these splits to differences between basic and translational researchers, to hype dynamics driven by venture capital, and to competitive pressures in the market economy.

From these tensions, the report’s authors extract a three-part agenda. First, the field must explicitly discuss what kinds of knowledge it deems necessary before clinical or regulatory translation, openly interrogating how much of the rush toward epigenetic innovation reflects informed judgment versus hype and a race for startup capital. Second, widely accepted methodological and analytical standards are needed to bridge basic science and application, a mission the International Society for Molecular and Clinical Epigenetics has begun promoting through interdisciplinary dialogue. Third, and most notably, the round tables revealed a largely untapped reflexivity among scientists, who are fully aware of the tension between complete mechanistic understanding and pragmatic innovation, yet rarely given structured forums to confront it. The CLEPIC round tables will become a regular conference feature, and the authors argue that such collaborative spaces, where natural and social scientists interrogate assumptions together, are an essential first step toward responsible epigenetic research and innovation, with reflexivity working in both directions.

Subject of Research: Societal and ethical readiness of epigenetic editing for clinical use and environmental epigenetics for regulatory risk assessment

Article Title: Meeting report on the round table discussions ‘epigenetics and society’ CLEPIC24

Article References: Habets, M. G., Rots, M. G., & Chiapperino, L. (2025). Meeting report on the round table discussions ‘epigenetics and society’ CLEPIC24. Epigenetics Communications, 5(1), Article 4. https://doi.org/10.1186/s43682-025-00035-1

Image Credits: AI Generated

DOI: 10.1186/s43682-025-00035-1

Keywords: epigenetics, epigenetic editing, responsible research and innovation, environmental epigenetics, precision environmental health, personalized medicine, chemical risk assessment, DNA methylation, CLEPIC24, science policy, statins, PCSK9